480 related articles for article (PubMed ID: 27129065)
1. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
Linnemann B; Erbe M
Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
[TBL] [Abstract][Full Text] [Related]
2. The diagnosis and treatment of Raynaud's phenomenon: a practical approach.
Pope JE
Drugs; 2007; 67(4):517-25. PubMed ID: 17352512
[TBL] [Abstract][Full Text] [Related]
3. Contemporary management of Raynaud's phenomenon and digital ischaemic complications.
Herrick AL
Curr Opin Rheumatol; 2011 Nov; 23(6):555-61. PubMed ID: 21885977
[TBL] [Abstract][Full Text] [Related]
4. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
5. [Raynaud's syndrome, 2011].
Takáts A; Garai I; Papp G; Hevér T; Csiki E; András C; Csiki Z
Orv Hetil; 2012 Mar; 153(11):403-9. PubMed ID: 22390864
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
[TBL] [Abstract][Full Text] [Related]
7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic management of acral manifestations of systemic sclerosis].
Meyer MF; Daigeler A; Lehnhardt M; Steinau HU; Klein HH
Med Klin (Munich); 2007 Mar; 102(3):209-18. PubMed ID: 17345017
[TBL] [Abstract][Full Text] [Related]
9. Raynaud, digital ulcers and calcinosis in scleroderma.
Nitsche A
Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
11. Part II: The treatment of primary and secondary Raynaud's phenomenon.
Curtiss P; Svigos K; Schwager Z; Lo Sicco K; Franks AG
J Am Acad Dermatol; 2024 Feb; 90(2):237-248. PubMed ID: 35809802
[TBL] [Abstract][Full Text] [Related]
12. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
Botzoris V; Drosos AA
Joint Bone Spine; 2011 Jul; 78(4):341-6. PubMed ID: 21183379
[TBL] [Abstract][Full Text] [Related]
13. Ulnar artery involvement in systemic sclerosis (scleroderma).
Taylor MH; McFadden JA; Bolster MB; Silver RM
J Rheumatol; 2002 Jan; 29(1):102-6. PubMed ID: 11824945
[TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
15. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Raynaud's phenomenon.
García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
[TBL] [Abstract][Full Text] [Related]
17. Raynaud's phenomenon: Current concepts.
Stringer T; Femia AN
Clin Dermatol; 2018; 36(4):498-507. PubMed ID: 30047433
[TBL] [Abstract][Full Text] [Related]
18. Raynaud's phenomenon-an update on diagnosis, classification and management.
Pauling JD; Hughes M; Pope JE
Clin Rheumatol; 2019 Dec; 38(12):3317-3330. PubMed ID: 31420815
[TBL] [Abstract][Full Text] [Related]
19. Raynaud's Syndrome: a neglected disease.
Poredos P; Poredos P
Int Angiol; 2016 Apr; 35(2):117-21. PubMed ID: 25673314
[TBL] [Abstract][Full Text] [Related]
20. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
